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ABSTRACT-Thirty patients with metastatic renal cell cancer were treated by renal infarction, 
followed by delayed nephrectomy. All cases were collected over an eighteen-month period, with a 
minimum follow-up of one year There were no complete remissions and only one partial remission, 
which lasted twenty-one months before progression of disease. Three patients had stable disease for 
at least six months, but eventually all patients showed evidence of progression. After tumor progres- 
sion was documented patients were treated with intramuscular medroxyprogesterone acetate 
(Depo-Provera) 800 mg per week. No patient responded to this therapy. Overall, a 28 per cent one- 
year survival and a seven-month median survival were realized, which is similar to other series in 
which no therapy or palliative nephrectomy was performed. We conclude that infarction and 
nephrectomy is not an effective modality in the treatment of metastatic renal cell carcinoma. In 
addition, medroxyprogesterone was not shown to be significantly active against renal cancer in this 
study. 
One fourth to one half of patients with renal 
cell carcinoma are found to have metastatic dis- 
ease at the time of initial presentation.1*2 His- 
torically, frustration has been the only apt 
description of the efforts to treat this disease 
with chemotherapy, radiation therapy, hor- 
monal and immunotherapy.3 However, several 
investigators have suggested that renal infarc- 
tion followed by delayed nephrectomy, with 
*This investigation was supported in part by the following PHS 
Cooperative Agreement grant numbers awarded by the National 
Cancer Institute, DHHS: CA-20319, CA-12213, CA-27057, CA- 
03392, CA-22411, CA-12014, and CA-32102. 
concomitant institution of progestin therapy, 
offered improved survival.4’5 The Southwest 
Oncology Group, attempting to corroborate 
this information, studied 31 consecutive pa- 
tients with metastatic renal cell carcinoma, us- 
ing infarction-nephrectomy only as the initial 
therapeutic modality. 
Material and Methods 
Thirty-one eligible patients were registered 
between January, 1980, and July, 1981, with a 
minimal one-year follow-up. Thirty patients 
were evaluable. Eligible patients were those 
with disseminated renal cell cancer with a 
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measurable lesion, in whom the metastatic dis- 
ease was not resectable at the time of nephrec- 
tomy. All patients had an expected survival of at 
least three months and were medically capable 
of tolerating the intended nephrectomy. Exclu- 
sions included prior irradiation, chemotherapy, 
or progestin therapy. Pretreatment studies in- 
cluded intravenous pyelogram, computerized 
tomography (CT) scan of the abdomen, renal 
and celiac arteriogram, pulmonary tomograms 
or CT of the lung, bone and liver scans, and a 
complete battery of metabolic tests. After eligi- 
bility had been determined, the involved kid- 
ney was infarcted. The technique has been 
described previous19 and in most instances Gel- 
foam pledgets were injected directly into the re- 
nal artery, followed by placement of Gianturco 
coils for complete renal artery occlusion. The 
patients were monitored closely in the postin- 
farction period, which lasted between six and 
nine days. 
Complete remission was defined as disap- 
pearance of all clinically active tumor for a 
minimum of four weeks. Partial remission was 
a 50 per cent or greater decrease in the cross- 
section diameter of the lesion maintained a 
minimum of four weeks. 
When progression of disease was identified, 
each patient was started on medroxyproges- 
terone 800 mg intramuscularly per week and 
followed until disease progression. The patients 
were then allowed to receive other modalities of 
treatment, but were followed until death. 
Results 
Thirty patients were followed a minimum of 
one year. One perioperative death occurred. No 
complete responses and one partial response 
lasting twenty-one months was achieved. Six 
patients were alive at the end of the study at 
twenty-six, twenty-five, fifteen, fifteen, four- 
teen, and twelve months. Twenty-four patients 
died within the range of the study. Only 4 pa- 
tients (13 % ), including the partial remission, 
had stable disease for at least six months after 
the infarction-nephrectomy. These 4 included 2 
males with lung metastases, a female with peri- 
hilar nodes, and, the partial remission, a male 
with chest-wall metastasis. Only 28 per cent of 
the patients survived one year, and the median 
survival was seven months. The median time to 
progression after infarction-nephrectomy was 
eight weeks. Of eight patients who survived one 
year, five had evidence of progression before the 
twelve-month mark. Only 3 of 11 patients with 
lung-only metastasis lived one year, despite the 
historic suggestions that these patients were the 
ones most likely to respond. 3 Interestingly, 2 pa- 
tients had evidence of partial remission of lung 
metastases, while other metastatic deposits 
grew. All patients eventually showed progres- 
sion of disease, and those still living are now on 
other forms of therapy. 
Seventeen patients presented with single or- 
gan metastases, 11 of these being lung only. 
Thirteen patients presented with multiple or- 
gan metastases. The most common metastatic 
sites in 30 patients were the lung (21), bone (6), 
and liver (4). 
Pathologic evaluation after nephrectomy re- 
vealed capsule invasion in 65 per cent, positive 
nodes in the perihilar region in 24 per cent, and 
microscopic venous involvement in 55 per cent. 
The degree of infarction seen on the pathologic 
specimen ranged from multifocal to massive, 
without apparent bearing on the subsequent 
survival. 
The possibility of hyperthermia creating a 
tumor response was evaluated, as it was com- 
mon for fever to develop in the postinfarction 
period. Only 1 of 3 patients in whom signifi- 
cant and sustained fever developed postinfarc- 
tion was alive at one year. Two of 8 patients 
who had moderate fever were alive at one year, 
and 5 of 18 patients with little or no fever were 
alive for greater than one year. 
Patients who exhibited progression after in- 
farction-nephrectomy were prescribed medroxy- 
progesterone, and 18 patients are evaluable at 
this time. There were no complete or partial re- 
sponses, and only 2 of 18 were stable for at least 
six months. The average time to progression on 
medroxyprogesterone was 2.5 months. The 2 
patients who were stable for six months both 
died during the study, at twelve and fourteen 
months after the initial infarction-nephrec- 
tomy. 
Postinfarction problems were quite rare, al- 
though most patients had significant pain. In a 
few of the patients severe nausea and ileus de- 
veloped which, in some cases, required nasogas- 
tric suction. No mortalities occurred in the post- 
infarction period, and the only postoperative 
death occurred in a patient with advanced 
metastatic liver disease, who died fourteen days 
postnephrectomy of a cerebrovascular acci- 
dent. No apparent complications of the arterio- 
gram or embolization itself occurred, although 
the risk of embolization to the lower extremities 
or bowel was a technical possibility. 
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Comment 
The proposed mechanism of response to in- 
farction-nephrectomy was thought to represent 
stimulation of the host immune system second- 
ary to a shower of tumor antigens released into 
the circulation after the infarction.4 Whether 
this hypothesized stimulation represents a cell- 
mediated response, humoral antibody response, 
or a reduction of blocking factors is unknown. 
The end result, however, suggests that the im- 
mune response was not significant enough to 
achieve an active role against the spreading 
cancer. The high response rate of previously re- 
ported M.D. Anderson series has apparently 
not been found in subsequent patients treated 
by them using similar methods, although they 
still believe that lung-only metastases fare bet- 
ter with infarction-nephrectomy medroxypro- 
gesterone.6 This suggestion was not confirmed 
in our study since only 3 of 11 patients with 
lung-only metastasis survived more than one 
year. Anecdotal cases in the literature of re- 
sponses to infarction-nephrectomy have been 
reported, but probably represent the rare cases 
of spontaneous remission which have been re- 
ported in the past with palliative nephrectomy.5 
The results of renal artery embolization with 
delayed nephrectomy as sole therapy for meta- 
static renal cell cancer are not encouraging. In 
addition, we have not been able to demonstrate 
activity of medroxyprogesterone against renal 
cell cancer. 
Chemotherapeutic agents that have activity 
against renal cell cancer need to be developed. 
To date, hormonal and immune therapy have 
not demonstrated consistent activity against re- 
nal cell cancer, but certainly are no worse than 
chemotherapy. Research for active agents 
should continue in all areas of anti-tumor 
therapy. 
1221 Madison #1210 
Seattle, Washington 98104 
(DR. GOTTESMAN) 
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